Related references
Note: Only part of the references are listed.Acute-Onset Type 1 Diabetes that Developed During the Administration of Olanzapine
Kenji Iwaku et al.
INTERNAL MEDICINE (2017)
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia - a short version for primary care
Alkomiet Hasan et al.
INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE (2017)
Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis
Britta Galling et al.
WORLD PSYCHIATRY (2017)
Suicide Prevention in Schizophrenia: Do Long-Acting Injectable Antipsychotics (LAIs) have a Role?
Maurizio Pompili et al.
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS (2017)
Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders
Cherrie Galletly et al.
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY (2016)
An update of safety of clinically used atypical antipsychotics
L. Orsolini et al.
EXPERT OPINION ON DRUG SAFETY (2016)
Clozapine Underutilization in the Treatment of Schizophrenia How Can Clozapine Prescription Rates Be Improved?
Jan P. A. M. Bogers et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2016)
Effect of Serum Leptin on Weight Gain Induced by Olanzapine in Female Patients with Schizophrenia
Nobuto Tsuneyama et al.
PLOS ONE (2016)
Do Atypical Antipsychotics Have Antisuicidal Effects? A Hypothesis-Generating Overview
Maurizio Pompili et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Role of serotonin 5-HT2C and histamine H1 receptors in antipsychotic-induced diabetes: A pharmacoepidemiological-pharmacodynamic study in VigiBase
Francois Montastruc et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2015)
Evaluation of the pharmacokinetics, safety and clinical efficacy of ziprasidone for the treatment of schizophrenia and bipolar disorder
Roberto Mandrioli et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2015)
Antipsychotic Treatment and Mortality in Schizophrenia
Minna Torniainen et al.
SCHIZOPHRENIA BULLETIN (2015)
Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level
MARC DE HERT et al.
World Psychiatry (2015)
Prevalence of Cardiovascular and Metabolic Events in Patients Prescribed Clozapine: A Retrospective Observational, Clinical Cohort Study
Natalie Hyde et al.
CURRENT DRUG SAFETY (2015)
Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study
Jan Volavka et al.
CNS SPECTRUMS (2014)
A Naturalistic Comparison of the Long-Term Metabolic Adverse Effects of Clozapine Versus Other Antipsychotics for Patients With Psychotic Illnesses
Anne C. Kelly et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2014)
Modulation of behavior by the histaminergic system: Lessons from H1R-and H2R-deficient mice
Erich H. Schneider et al.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS (2014)
Almost All Antipsychotics Result in Weight Gain: A Meta-Analysis
Maarten Bak et al.
PLOS ONE (2014)
Polymorphisms of the leptin and HTR2C genes and clozapine-induced weight change and baseline BMI in patients with chronic schizophrenia
Shi Hyun Kang et al.
PSYCHIATRIC GENETICS (2014)
Contribution of baseline body mass index and leptin serum level to the prediction of early weight gain with atypical antipsychotics in schizophrenia
Benjamin Cortes et al.
PSYCHIATRY AND CLINICAL NEUROSCIENCES (2014)
Blood levels of glucose and insulin and insulin resistance in patients with schizophrenia on clozapine monotherapy
Adam Wysokinski
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS (2014)
The Role of Hypothalamic H1 Receptor Antagonism in Antipsychotic-Induced Weight Gain
Meng He et al.
CNS DRUGS (2013)
Estimating Dopamine D2 Receptor Occupancy for Doses of 8 Antipsychotics A Meta-Analysis
Irene M. Lako et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2013)
Adjunctive Aripiprazole Versus Placebo for Antipsychotic-Induced Hyperprolactinemia: Meta-Analysis of Randomized Controlled Trials
Xianbin Li et al.
PLOS ONE (2013)
Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis
Hoda Moteshafi et al.
EXPERT OPINION ON DRUG SAFETY (2012)
Safety and tolerability of antipsychotic polypharmacy
Juan A. Gallego et al.
EXPERT OPINION ON DRUG SAFETY (2012)
Comparative effectiveness of switching antipsychotic drug treatment to aripiprazole or ziprasidone for improving metabolic profile and atherogenic dyslipidemia: a 12-month, prospective, open-label study
Yuejin Chen et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2012)
Beyond the body mass index: tracking body composition in the pathogenesis of obesity and the metabolic syndrome
M. J. Mueller et al.
OBESITY REVIEWS (2012)
Antipsychotic Polypharmacy in Inpatients with Schizophrenia in Asia (2001-2009)
Y. -T. Xiang et al.
PHARMACOPSYCHIATRY (2012)
Antipsychotics, dopamine D2 receptor occupancy and clinical improvement in schizophrenia: A meta-analysis
Zeynep Yilmaz et al.
SCHIZOPHRENIA RESEARCH (2012)
The Role of Leptin in Antipsychotic-Induced Weight Gain: Genetic and Non-Genetic Factors
Fabio Panariello et al.
JOURNAL OF OBESITY (2012)
Association of antipsychotic polypharmacy with health service cost: a register-based cost analysis
Lone Baandrup et al.
EUROPEAN JOURNAL OF HEALTH ECONOMICS (2012)
A Randomized Trial Examining the Effectiveness of Switching From Olanzapine, Quetiapine, or Risperidone to Aripiprazole to Reduce Metabolic Risk: Comparison of Antipsychotics for Metabolic Problems (CAMP)
T. Scott Stroup et al.
AMERICAN JOURNAL OF PSYCHIATRY (2011)
Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study
Fuminari Misawa et al.
BMC PSYCHIATRY (2011)
Effect of Antipsychotic Medications on Glucose and Lipid Levels
Parminder S. Chaggar et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Predicting Dopamine D2 Receptor Occupancy From Plasma Levels of Antipsychotic Drugs A Systematic Review and Pooled Analysis
Hiroyuki Uchida et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2011)
Antipsychotic polypharmacy: A survey study of prescriber attitudes, knowledge and behavior
Christoph U. Correll et al.
SCHIZOPHRENIA RESEARCH (2011)
National Trends in Psychotropic Medication Polypharmacy in Office-Based Psychiatry
Ramin Mojtabai et al.
ARCHIVES OF GENERAL PSYCHIATRY (2010)
Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial
W. Wolfgang Fleischhacker et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2010)
Metabolic side effects of antipsychotic drug treatment - pharmacological mechanisms
Gavin P. Reynolds et al.
PHARMACOLOGY & THERAPEUTICS (2010)
Are Weight Gain and Metabolic Side Effects of Atypical Antipsychotics Dose Dependent? A Literature Review
Viktoria Simon et al.
JOURNAL OF CLINICAL PSYCHIATRY (2009)
Explicit versus implicit review to explore combination antipsychotic prescribing
Amanda Wheeler
JOURNAL OF EVALUATION IN CLINICAL PRACTICE (2009)
Atypical Antipsychotic Drugs and the Risk of Sudden Cardiac Death
Wayne A. Ray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Rapidly developing hyperglycemia during treatment with olanzapine
Izchak Kohen et al.
ANNALS OF PHARMACOTHERAPY (2008)
Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: An 8-week, randomized, double-blind, placebo-controlled trial
Jae Seung Chang et al.
JOURNAL OF CLINICAL PSYCHIATRY (2008)
Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial
H. -J. Assion et al.
PHARMACOPSYCHIATRY (2008)
Short- and long-term effects of antipsychotic drug treatment on weight gain and H1 receptor expression
Mei Han et al.
PSYCHONEUROENDOCRINOLOGY (2008)
Adjunctive treatment with a dopamine partial agonist, aripiprazole, for anti psychotic-induced hyperprolactinemia: A placebo-controlled trial
Joo-Cheol Shim et al.
AMERICAN JOURNAL OF PSYCHIATRY (2007)
Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain - A pilot study
Sun H. Kim et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2007)
Is ciozapine-aripiprazole combination a useful regime in the management of treatment-resistant schizophrenia?
Kanapathippillai Karunakaran et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2007)
Risperidone augmentation for schizophrenia partially responsive to clozapine: A double-blind, placebo-controlled trial
Oliver Freudenreich et al.
SCHIZOPHRENIA RESEARCH (2007)
A case series: Evaluation of the metabolic safety of aripiprazole
Marc De Hert et al.
SCHIZOPHRENIA BULLETIN (2007)
Comparison of clozapine-amisulpride and clozapine-quetiapine combinations for patients with schizophrenia who are partially responsive to clozapine: A single-blind randomized study
Yasin Genc et al.
ADVANCES IN THERAPY (2007)
Metabolic drug interactions with newer antipsychotics: A comparative review
Edoardo Spina et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2007)
Antipsychotic induced metabolic abnormalities: An interaction study with various PPAR modulators in mice
D. K. Arulmozhi et al.
LIFE SCIENCES (2006)
Benefits of combining aripiprazole to clozapine: Three case reports
Fabio Lopes Rocha et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2006)
Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia
Ren-Rong Wu et al.
PSYCHOPHARMACOLOGY (2006)
Metabolic findings from the CATIE trial and their relation to tolerability
Henry A. Nasrallah
CNS SPECTRUMS (2006)
Comparison between risperidone, olanzapine, and clozapine in the management of chronic schizophrenia: A naturalistic prospective 12-week observational study
Rael D. Strous et al.
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL (2006)
Clozapine alone versus clozapine and risperidone with refractory schizophrenia
WG Honer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Determinants of antipsychotic polypharmacy in psychiatric inpatients:: a prospective study
B Biancosino et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2005)
Effectiveness of clozapine, olanzapine, quetiapine, risperidone, and haloperidol monotherapy in reducing hostile and aggressive behavior in outpatients treated for schizophrenia: a prospective naturalistic study (IC-SOHO)
I Bitter et al.
EUROPEAN PSYCHIATRY (2005)
Research on adverse drug events.: I.: Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes
JS Silvestre et al.
METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY (2005)
A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: Efficacy and safety
AEA Yagcioglu et al.
JOURNAL OF CLINICAL PSYCHIATRY (2005)
Clozapine augmented with risperidone in the treatment of schizophrenia: A randomized, double-blind, placebo-controlled trial
RC Josiassen et al.
AMERICAN JOURNAL OF PSYCHIATRY (2005)
Suicide and awareness of illness in schizophrenia: An overview
M Pompili et al.
BULLETIN OF THE MENNINGER CLINIC (2004)
Prevalence of hyperprolactinemia in schizophrenia: Association with typical and atypical antipsychotic treatment
J Montgomery et al.
JOURNAL OF CLINICAL PSYCHIATRY (2004)
A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States
JB Buse et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2003)
Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations
O Freudenreich et al.
ACTA PSYCHIATRICA SCANDINAVICA (2002)
The safety and pharmacokinetics of quetiapine when coadministered with haloperidol, risperidone, or thioridazine
SG Potkin et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2002)
Clozapine-associated diabetes
E Koller et al.
AMERICAN JOURNAL OF MEDICINE (2001)
Management of treatment resistance in schizophrenia
RR Conley et al.
BIOLOGICAL PSYCHIATRY (2001)
A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder
RR Conley et al.
AMERICAN JOURNAL OF PSYCHIATRY (2001)
An open trial of risperidone augmentation of partial response to clozapine
CG Taylor et al.
SCHIZOPHRENIA RESEARCH (2001)
Addition of risperidone to clozapine therapy in chronically psychotic inpatients
IW de Groot et al.
JOURNAL OF CLINICAL PSYCHIATRY (2001)
Bodyweight gain with atypical antipsychotics - A comparative review
T Wetterling
DRUG SAFETY (2001)
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study
DC Henderson et al.
AMERICAN JOURNAL OF PSYCHIATRY (2000)
Share Paper
